Zydus Lifesciences Q4 Revenue Up 16% YoY, Announces Dividend and Buyback

Zydus Lifesciences reported Q4 FY26 revenue growth of 16.2% YoY to ₹75.87 billion and EBITDA growth of 20.2% to ₹25.54 billion.
The Board recommended a 100% dividend for FY26 and approved a share buyback of up to ₹11 billion at ₹1,150 per share.
Consumer Wellness business grew 61.1% YoY while North America formulations declined 5.7% in Q4 FY26.
Company acquired Assertio Holdings for $166 million and launched multiple biosimilars including world's first Nivolumab biosimilar.